A Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxicity.
Cancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
It was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer drug Piqray (alpelisib), the first and only treatment developed specifically for patients with a PIK3CA mutation in HR+/HER2-advanced breast cancer.
https://european-biotechnology.com/wp-content/uploads/2024/04/drmartintreder.jpg336336h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-05-27 16:02:472019-05-27 16:02:47Affimed parts with CSO
The FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.
Rare functional sugars provide huge market opportunities. European Biotechnology spoke with Stefan Jennewein, Founder and CEO of Jennewein Biotechnologies, about the company’s strategy and its latest expansions to the Chinese market.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Spring_2019_Jennewein01_tg.jpg5631000h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-05-24 13:43:322019-05-24 13:43:32Functional sugars made by biotech for everyone
At BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.
Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.
https://european-biotechnology.com/wp-content/uploads/2024/04/EUministerCRISPR_123rf_Andrii_Panchyk_110478118_s.jpg611783Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-22 10:25:392019-05-22 10:25:39EU ministers set to exclude CRISPR crops from GMO legislation
Make leukaemia therapy safer
Latest NewsA Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxicity.
Nanobiotix spins out Curadigm
Latest NewsCancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
Double win for Novartis
Latest NewsIt was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer drug Piqray (alpelisib), the first and only treatment developed specifically for patients with a PIK3CA mutation in HR+/HER2-advanced breast cancer.
Affimed parts with CSO
AppointmentsDr. Martin Treder has informed Affimed that he intends to step down from his position as Chief Scientific Officer to pursue new opportunities.
Most expensive gene therapy globally approved
Latest NewsThe FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.
Functional sugars made by biotech for everyone
OpinionRare functional sugars provide huge market opportunities. European Biotechnology spoke with Stefan Jennewein, Founder and CEO of Jennewein Biotechnologies, about the company’s strategy and its latest expansions to the Chinese market.
Mark Hammond joins PBD Biotech
AppointmentsNovel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the company’s expansion.
Healthy figures from Spain
Latest NewsAt BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.
Chiesi acquires ex-US Raxone marketing rights
Latest NewsChiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.
EU ministers set to exclude CRISPR crops from GMO legislation
Latest NewsEU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation.